Last reviewed · How we verify
will not receive PO treatment
will not receive PO treatment is a Small molecule drug developed by Rambam Health Care Campus. It is currently in Phase 1 development.
At a glance
| Generic name | will not receive PO treatment |
|---|---|
| Sponsor | Rambam Health Care Campus |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia (PHASE3)
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (PHASE1, PHASE2)
- Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (PHASE2)
- Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) (PHASE3)
- Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty (PHASE4)
- A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- will not receive PO treatment CI brief — competitive landscape report
- will not receive PO treatment updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI
Frequently asked questions about will not receive PO treatment
What is will not receive PO treatment?
will not receive PO treatment is a Small molecule drug developed by Rambam Health Care Campus.
Who makes will not receive PO treatment?
will not receive PO treatment is developed by Rambam Health Care Campus (see full Rambam Health Care Campus pipeline at /company/rambam-health-care-campus).
What development phase is will not receive PO treatment in?
will not receive PO treatment is in Phase 1.